Can genes normally expressed only in the eye be activated in brain tumours? The phenomenon, though surprising, has been observed in certain types of medulloblastoma, paediatric tumours of the cerebellum. Researchers from the CNRS, Institut Curie, Inserm and Université Paris-Sud, together with researchers at St. Jude Children’s Research Hospital (Memphis, United States), have pinpointed the role of these genes in the tumour process, thus offering new therapeutic targets. Their findings appear in the 12 March 2018 edition of Cancer Cell.
Medulloblastoma is treated with a combination of surgery, radiotherapy and chemotherapy, which results in a survival rate of 80 percent, albeit with significant side effects. Group 3 medulloblastoma, associated with frequent rates of recurrence and a much lower survival rate, is characterised by the expression of the so-called photoreceptor program gene cluster. Normally, these genes are only expressed in the retina, where they define photoreceptor identity and ensure that light signals are converted into nerve impulses.
Given that they are not expressed during the normal development of the cerebellum, activation of these genes in medulloblastoma is very surprising. Aberrant differentiation programs unrelated to the tissue in which the tumour originates have already been found in other types of cancer, but were never thought to be directly involved in the tumour process.
Celio Pouponnot, CNRS researcher at the Institut Curie, together with Franck Bourdeaut, medical researcher at the Institut Curie, and Paul Northcott at St. Jude Children’s Research Hospital in Memphis, United States, decided to examine the role the photoreceptor program could play in a medulloblastoma.
The presence of a protein called NRL within the photoreceptor program initially drew the attention of Celio Pouponnot’s team, which, for many years, has studied a family of proteins similar to NRL involved in the formation of cancers. Researchers also identified the role of another protein specific to the retina: CRX. Strikingly, this study shows that both these factors are involved in the medulloblastoma by activating key genes: CCND2, which promotes cell proliferation, and BCL2L1, which inhibits cell death (apoptosis).
The research team then used pharmacological agents to target these anti-apoptotic proteins in preclinical models by grafting human medulloblastoma cells into mice. This treatment shrunk the tumour and extended the lives of the mice, proving the potential of this therapeutic target. These results, however, cannot be directly transposed to children, for whom such pharmacological agents could be toxic.
More generally, this study shows the potential benefit of studying signs of aberrant differentiations in cancer processes, highlighting a new area in cancer research.
Cancer Cell (2018). DOI: 10.1016/j.ccell.2018.02.006